{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T19:04:19Z","timestamp":1775156659780,"version":"3.50.1"},"reference-count":10,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Surgical treatment is generally the standard therapeutic regimen used for primary bilateral macronodular adrenal cortical disease (PBMACD). However, in cases for which surgery is difficult or in which there is mild cortisol hypersecretion, metyrapone treatment can be selected. Although hypokalemia has been occasionally noted following metyrapone administration for Cushing syndrome associated with an adrenal adenoma, all such cases have been reported to be transient. Hypokalemia induced by metyrapone treatment is thought to occur due to excessive suppression of cortisol secretion, resulting in overproduction of adrenocorticotropic hormone from the pituitary gland, ultimately leading to excessive production of 11-deoxycorticosterone (DOC) in the adrenal cortex. A 52-year-old man diagnosed with PBMACD and started on metyrapone treatment subsequently presented with persistent hypokalemia. Interestingly, following initiation of metyrapone, blood test findings indicated marginal changes in serum cortisol, adrenocorticotropic hormone, and dehydroepiandrosterone sulfate levels, even when DOC levels were already markedly elevated. In addition to the effects of metyrapone, the present findings suggest a unique DOC synthesis regulatory mechanism involved in the pathogenesis of PBMACD.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae015","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:32:11Z","timestamp":1706805131000},"source":"Crossref","is-referenced-by-count":4,"title":["Prolonged Hypokalemia Following Metyrapone Treatment for Primary Bilateral Macronodular Adrenal Cortical Disease"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7091-5639","authenticated-orcid":false,"given":"Yonekazu","family":"Kidawara","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University , Nishinomiya, Hyogo 663-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7112-1585","authenticated-orcid":false,"given":"Miki","family":"Kakutani-Hatayama","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University , Nishinomiya, Hyogo 663-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-653X","authenticated-orcid":false,"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital , Kobe, Hyogo 650-0017 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University , Nishinomiya, Hyogo 663-8501 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"3","key":"2024022316570518600_luae015-B1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/ajcp\/96.3.334","article-title":"Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing syndrome","volume":"96","author":"Aiba","year":"1991","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2024022316570518600_luae015-B2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/archsurg.133.5.541","article-title":"Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathological correlation","volume":"133","author":"Swain","year":"1998","journal-title":"Arch Surg"},{"issue":"1","key":"2024022316570518600_luae015-B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1507\/endocrj.46.59","article-title":"A patient with preclinical Cushing syndrome and excessive DHEA-S secretion having unilateral adrenal carcinoma and contralateral adenoma","volume":"46","author":"Midorikawa","year":"1999","journal-title":"Endocr J"},{"issue":"2","key":"2024022316570518600_luae015-B4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.beem.2008.10.011","article-title":"ACTH-independent macronodular adrenal hyperplasia","volume":"23","author":"Andre","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"2024022316570518600_luae015-B5","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1210\/jc.2015-2662","article-title":"Unilateral adrenalectomy as a first-line treatment of Cushing syndrome in patients with primary bilateral macronodular adrenal hyperplasia","volume":"100","author":"Emmanuelle","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024022316570518600_luae015-B6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Lynnette","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024022316570518600_luae015-B7","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Eleni","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024022316570518600_luae015-B8","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1172\/JCI103988","article-title":"Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11\u03b2-hydroxylation","volume":"38","author":"Coppage","year":"1959","journal-title":"J Clin Invest"},{"issue":"22","key":"2024022316570518600_luae015-B9","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1056\/NEJMoa1215245","article-title":"Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia","volume":"369","author":"Louiset","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2024022316570518600_luae015-B10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1210\/js.2019-00210","article-title":"ARMC5 alterations in primary macronodular adrenal hyperplasia (PMAH) and the clinical state of variant carriers","volume":"3","author":"Kyo","year":"2019","journal-title":"J Endocr Soc"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/2\/luae015\/56748025\/luae015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/2\/luae015\/56748025\/luae015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T16:57:27Z","timestamp":1708707447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae015\/7595900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,8]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae015","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,1,8]]},"article-number":"luae015"}}